In short
Clinical trials are studying Alxn2220 in adults with transthyretin amyloid cardiomyopathy (ATTR-CM), a heart condition caused by amyloid buildup. The trials are looking at safety, effectiveness, and how well re-treatment works. They include Phase 2 and Phase 3 studies in adult patients.
Key points
- Clinical trials of Alxn2220 are studying adults with transthyretin amyloid cardiomyopathy (ATTR-CM), a heart condition linked to amyloid buildup. The trial data include one Phase 2 study and one Phase 3 study, both currently authorised. The Phase 2 study looks at markers of disease severity and the safety of re-treatment. The Phase 3 study compares Alxn2220 with placebo and measures total all-cause mortality and cardiovascular clinical events. Together, these studies focus on how well the treatment may work and how safe it is in adult patients with ATTR-CM.
Trial overview
The available trial data show two interventional studies of Alxn2220 in adults with transthyretin amyloid cardiomyopathy (ATTR-CM), which is a heart disease linked to amyloid buildup. Both studies are listed as authorised.
One study is Phase 2 and includes 35 participants, while the other is Phase 3 and plans to enroll 1,000 participants. Together, they focus on whether Alxn2220 can help adults with ATTR-CM and how safe it is to use in these study settings.
Phase 2 study: re-treatment and disease markers
The Phase 2 trial is titled as a multicenter study of the effects of Alxn2220 on markers of disease severity and the safety of re-treatment in patients with ATTR-CM. Multicenter means the study is being done at more than one site, which can help include a wider group of patients.
This study aims to evaluate the pharmacodynamics of re-treatment, which means how the study treatment affects the body after it is given again. The main outcomes are changes from baseline to Visit 16 in cMRI and scintigraphy, which are imaging tests used to look at the heart and amyloid-related findings.
Phase 3 study: effectiveness and clinical events
The Phase 3 trial is designed to test whether Alxn2220 is effective, safe, and tolerable in adults with ATTR-CM. It compares Alxn2220 with a placebo, which is an inactive product used as a comparison group.
The brief summary says the study is assessing the difference between the Alxn2220 and placebo groups by looking at total occurrences of ACM and cardiovascular clinical events during the blinded treatment period. In simple terms, the trial is checking whether people taking Alxn2220 have fewer serious heart-related events than people taking placebo.
Who can participate
Based on the trial data, both studies are for adults with transthyretin amyloid cardiomyopathy (ATTR-CM). No other eligibility details are provided in the source data, so the main known requirement is having this condition and being an adult.
The Phase 2 study also focuses on patients who may receive re-treatment, so it is especially interested in people who have already had prior study treatment and are being studied again.
Main outcomes being measured
The Phase 2 study measures change from baseline, which means the difference between the starting point and the later visit in the same patient. Its main outcomes are cMRI and scintigraphy results at Visit 16.
The Phase 3 study measures the total occurrence of all-cause mortality and cardiovascular clinical events during the blinded treatment period. All-cause mortality means death from any cause, and cardiovascular events are serious problems related to the heart and blood vessels.
Study design terms explained
Placebo is used in the Phase 3 study so researchers can compare Alxn2220 with a product that does not contain the active study treatment. This helps show whether any differences in outcomes are likely due to the study treatment itself.
Authorised means the study has been approved to move forward in the setting described in the source data. Interventional means researchers are giving a treatment and then measuring the results.